Trial Profile
A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2016
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Scleroderma
- Focus Adverse reactions
- Sponsors MedImmune
- 11 Dec 2014 New trial record